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doi:10.1Objectives: Radial arteries are increasingly used as conduits for coronary artery bypass grafts. However, vaso-
spasm continues to be a major concern in radial artery grafts. Rho kinase plays a critical role in vascular con-
traction through phosphorylation of the regulatory subunit myosin phosphatase targeting subunit 1 (MYPT1)
of the myosin light chain phosphatase to inhibit myosin light chain phosphatase in vascular smooth muscle.
The purpose of this study was to evaluate the inhibitory effects of fasudil, a clinically used Rho kinase inhibitor,
on Rho kinase activity, myosin light chain phosphorylation, in vitro contraction, and in situ vasospasm in radial
arteries of patients undergoing coronary artery bypass grafting surgery.
Methods: The inhibitory efficacy of fasudil on vasoconstrictor-induced contraction and phosphorylation of
MYPT1 was examined in radial artery rings. In situ phosphorylation of MYPT1 was evaluated in nonspastic
and spastic radial arteries, and the effects of intraluminal administration of fasudil and verapamil–glyceryl
trinitrate (VG) on in situ free blood flow and phosphorylation of MYPT1 and myosin light chain were compared
in spastic radial arteries.
Results: Both fasudil and VG nearly fully inhibited noradrenaline- and serotonin-induced contraction of radial
artery rings. However, fasudil but not VG abolished MYPT1 phosphorylation. In spastic radial arteries phos-
phorylation of MYPT1 and myosin light chain was increased compared with that seen in nonspastic arteries.
Intraradial administration of fasudil induced a much larger increase in in situ free blood flow compared with
VG treatment. This antispastic effect of fasudil was accompanied by marked decreases in phosphorylation of
MYPT1 and myosin light chain.
Conclusions: Fasudil is a very effective Rho kinase inhibitor that deinhibits myosin light chain phosphatase and
powerfully relieves vasospasm in situ in radial arteries. (J Thorac Cardiovasc Surg 2011;142:e59-65)E
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SAs an important prognostic factor of coronary artery bypass
grafting (CABG), graft spasm increased the incidence of an-
gina and myocardial infarction during the perioperative pe-
riod.1 The radial artery (RA) and the great saphenous vein
are commonly used as composite grafts with the internal
thoracic artery.1-4 However, the RA is more prone to spasm
than the internal thoracic artery and great saphenous vein,
probably because of the spastic property of the thick
muscular wall and enhanced reactivity to vasoactive
mediators.1,5,6 Therefore improvement in harvesting
techniques and antispastic agents has been the subject of
intense investigation.1,5 A number of drugs have been usede Departments of General and Cardiothoracic Surgerya and Physiology,b
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The Journal of Thoracic and Cato prevent arterial graft spasm, which include a verapamil–
glyceryl trinitrate (VG) solution6-8; subtype-nonspecific
and specific phosphodiesterase inhibitors, such as papaverine
and olprinone6,9-11; and a-adrenergic blockers.11 Among
these antispasmodic agents, VG solution is considered to rep-
resent a relatively superior antispastic agent.6-8 Despite the
use of these antispasmodics, RA vasospasm remains
a problem that causes early graft failure after CABG.1,5,6
Therefore the most effective way to prevent and reverse
RA spasm is still under investigation.
Augmented smooth muscle contractility is thought to be
a major cause of vasospasm that is induced by various stimuli,
including mechanical trauma and vasoactive mediators.1,5,6
However, a detailed mechanism of vasospasm still remains
unclear. An increase in the intracelluar Ca2þ concentration by
contractile stimuli triggers phosphorylation of the 20-kd
myosin light chain (MLC) through activation of Ca2þ/
calmodulin-activated MLC kinase and initiates smooth
muscle contraction.12,13 Vasoactive receptor agonists also
activate the small guanosine triphosphatase Rho and its
effector, Rho kinase (ROCK), leading to inhibition of
the MLC-dephosphorylating enzyme MLC phosphatase
(MLCP), which acts to potentiate MLC kinase–catalyzedrdiovascular Surgery c Volume 142, Number 2 e59
Abbreviation and Acronyms
CABG ¼ coronary artery bypass grafting
5-HT ¼ 5-hydroxytryptamine
MLC ¼ myosin light chain
MLCP ¼ myosin light chain phosphatase
MYPT1 ¼ myosin phosphatase targeting
subunit 1
NA ¼ noradrenalin
RA ¼ radial artery
ROCK ¼ Rho kinase
VG ¼ verapamil–glyceryl trinitrate




SMLC phosphorylation and contraction in vascular smooth
muscle.12,13 ROCK inhibits MLCP through phosphorylating
the 110-kd myosin-targeting subunit myosin phosphatase tar-
geting subunit 1 (MYPT1) of MLCP. ROCK-dependent
MLCP inhibition is implicated in pathological vascular hyper-
contractile conditions; clinical trials have demonstrated that
fasudil, a ROCK inhibitor, is effective in suppressing vaso-
spasm after subarachnoid hemorrhage and coronary artery
spasm.14-18
Recently, it has been reported that ROCK inhibitors,
such as fasudil and Y27632, prevent agonist-induced vaso-
constriction in isolated human RAs in vitro19,20 and that
the mRNA and protein expression of Rho and ROCK in
the RA was increased compared with that seen in the
internal thoracic artery.21 In the present study we first ex-
amined the efficacy of fasudil on vasoactive agonist–
induced contraction and MLCP inhibition in isolated RA
rings. We then studied whether skeletonization-induced
in situ spasm of RA was accompanied by augmented
ROCK-mediated inhibition of MLCP and tested the re-
versing effects of intraradial fasudil application on spasm
and MLCP inhibition in RAs of patients undergoing
CABG. We demonstrate for the first time that intraradial
application of fasudil in the spastic RA effectively
increases in situ free blood flow with reversal of MLCP
inhibition.MATERIALS AND METHODS
Materials
The following reagents were used in the present study: 5-hydroxytryp-
tamine (5-HT; serotonin), noradrenalin (NA), papaverine, and mouse
monoclonal anti-MLC antibody (M4401; Sigma, St Louis, Mo); dithio-
threitol, trichloroacetic acid, and acetone (Wako Pure Chemicals, Osaka,
Japan); rabbit polyclonal anti-phospho (Thr853)-MYPT1 (36-003) antibody
(Upstate Biotechnology, Lake Placid, NY); rabbit polyclonal anti-MYPT1
antibody (PRB-457C; Covance, Berkley, Calif); rabbit polyclonal anti-
phospho (Ser19)-MLC (3675) antibody (Cell Signaling, Danvers, Mass);
fasudil (HA-1077; Asahi Chemical Industry, Fuji, Japan); verapamil and
olprinone (Eizai Pharm, Inc, Tokyo, Japan); and glyceryl trinitrate (nitro-
glycerin; Astellas Pharma, Inc, Tokyo, Japan).e60 The Journal of Thoracic and Cardiovascular SurgCollection of RAs and Measurement of In Situ Free
Blood Flow
RA specimens were collected from 26 patients (19 male and 7 female
patients) who underwent CABG with an RA graft at Kanazawa University
Hospital. The procedures and handling of human tissue were approved by
the ethical committee of Kanazawa University, and informed consent was
obtained from each patient before the study. The mean age of the patients
was 67.4  0.6 years. Among 26 patients, 16 had hypertension, 11 had di-
abetes mellitus, and 12 had hyperlipidemia. The patients received medica-
tions of coronary vasodilators, including nitrate (n ¼ 12), Ca2þantagonists
(n ¼ 13), and nicorandil (n ¼ 14); antiplatelet agents, including aspirin
(n ¼ 22) and clopidogrel (n ¼ 7; b-blockers (n ¼ 5); AT1 blocker
(n¼ 7); and statins (n¼ 18). Aspirin was not stopped before the operation,
and other agents were taken until the day before the operation.
For in vitro tension measurements, RA specimens were excised from
the distal or proximal ends of RA grafts; placed in ice-cold modified
Krebs–Henseleit buffer comprising 119 mmol/L NaCl, 4.7 mmol/L KCl,
1.2 mmol/L KH2PO4, 1.5 mmol/L CaCl2, 25 mmol/L NaHCO3, and
11 mmol/L glucose, which had been aerated with a mixed gas consisting
of 95% O2 and 5% CO2; and transported to the laboratory.
RAs that exhibited vasospasm during harvest by using electric cautery in
a semiskeletonized fashionwere used formeasurements of in situ free blood
flow before and after intraradial administration of antispasmodics. Each ar-
tery was allowed to bleed freely for 10 seconds for the determination of free
blood flow. Then patients received intraradial injection of 1.5 mL of either
fasudil (1.5 mg/mL) or VG (30 mmol/L verapamil and 30 mmol/L glyceryl
trinitrate)8 in Ringer’s solution (supplemented with 0.67 mmol/L NaHCO3
and 1.67U/mL heparin) from the distal end of the bilateral RAs, and the dis-
tal end of the bilateral RAswas occludedwith a hemoclip. The right and left
RAs were randomly assigned to fasudil or VG, and fasudil or VG was in-
fused into the RAs in random order. Maximal dilatation of the RAwas ob-
served by 5 minutes after infusion of fasudil or VG solution. At 5 minutes,
bilateral RAs were declipped, and in situ free blood flow was determined
again. For the determination of phosphorylation of MYPT1 and MLC,
the specimens were excised from the distal ends of the RA before and after
antispasmodic injection andwere rapidly frozen in an acetone dry ice slurry
containing 20 mmol/L dithiothreitol and 10% trichloroacetic acid.22 As
stated in the Results section, VG turned out to be less effective at increasing
free blood flow than fasudil. Therefore VG-treated RAs subsequently
received intraradial application of fasudil before use as grafts.Determinations of Tension and Phosphorylation of
MYPT1 and MLC
RAs were dissected free of adhering connective tissues and fat, cut into
rings of about 4 to 5 mm in length (total of 61 rings from 15 patients), and
denuded of endothelium by means of gentle rubbing of the internal surface
with a wooden stick. The rings were mounted under 1 g of resting tension,
and the isometric tension was determined as described previously.22 The
tension during the measurement was expressed as the percentage of the
maximum force during KCl precontraction.22
Isometrically contracted RA rings were rapidly frozen in acetone dry ice
slurry and washed, as described previously.22 Fixed tissues were homoge-
nized in a homogenization buffer of the following composition: 20 mmol/L
Tris/HCl (pH 7.5); 100 mmol/L NaF; 1 mmol/L Na3VO4; 1 mmol/L phe-
nylmethylsulfonyl fluoride; 0.1% sodium dodecylsulfate; 2 mmol/L
ethyleneglycol-bis-(b-aminoethylether)-N,N,N0,N0-tetraacetic acid; 0.5%
NP-40; and 20 mg/ml each of leupeptin and aprotinin. The samples
(80 mg of protein) were separated on 8% (for MYPT1) or 15% (for
MLC) sodium dodecylsulfate–polyacrylamide gel electrophoresis, fol-
lowed by Western blot analysis with either phospho(Thr853)-MYPT1– or
phospho(Ser19)-MLC–specific antibodies. The same samples were also
analyzed by means of Western blotting with antibodies that recognize
both phospho- and non–phospho-proteins. The amounts ofery c August 2011
Takagi et al Evolving Technology/Basic Sciencephospho(Thr853)-MYPT1 and phospho(Ser19)-MLC quantified by means
of densitometry were normalized for total amounts of MYPT1 and MLC,
respectively, in each sample, and the normalized quantified data of the
phospho-proteins were expressed as multiples over the values in the
nontreated RA ring and nonspastic RA, which are expressed as 1.0.
Statistical Analysis
All data are shown as means standard errors of the mean. One-way or
2-way analysis of variance followed by the Bonferonni post test or paired or
nonpaired 2-tailed Student’s t test was performed to determine the statisti-
cal significance of differences between mean values.FIGURE 1. Fasudil inhibits receptor agonist–induced contraction of ra-
dial artery rings in a dose-dependent manner. A, Dose-dependent inhibition





Fasudil Inhibits Agonist-Induced RA Contraction
We studied the effect of fasudil on agonist-induced iso-
metric contraction of RA rings. The representative time-
course study shows that fasudil inhibited NA-induced
contraction in a dose-dependent manner when fasudil was-
cumulatively added to rings precontracted by NA (Figure 1,
A). Fasudil also inhibited 5-HT–induced contraction in
a dose-dependent manner (Figure 1, B). Fasudil displayed
similar inhibitory potencies for both receptor agonists
(inhibitory concentration of 50% values of 2.94  0.34
mmol/L and 3.00  0.26 mmol/L for NA and 5-HT, respec-
tively). Fasudil at 30 mmol/L suppressed NA- and 5-HT–
induced contraction of all tested RA preparations from
different patients by more than 90% (Figure 1, B).
We compared the efficacies of fasudil (30 mmol/L) and
other antispasmodics (ie, VG,6-8 the nonselective phospho-
diesterase inhibitor papaverine,6,11 and the phospho-
diesterase III–specific inhibitor olprinone9,10) in inhibiting
NA- and 5-HT–induced contraction. Fasudil markedly
inhibited NA- and 5-HT–induced contraction (9.2% 
6.4% and 8.9%  4.9% of maximal tension elicited by
NA and 5-HT, respectively), which was comparable with
the effects of VG (8.5%  5.1% and 8.5%  4.8% of
maximal tension elicited by NA and 5-HT, respectively;
Figure 2, A). Olprinone (30 mmol/L) and papaverine
(30 mmol/L) considerably inhibited contraction induced
by NA and 5-HT (22.2% 4.2% and 28.1% 2.5% after
olprinone treatment and 28.1%  3.9% and 27.1% 
3.6% after papaverine treatment, respectively), although
the extents of inhibition were less than those seen with fasu-
dil and VG (Figure 2, A). Thus these antispasmodics all
exhibited substantial efficacy in inhibiting receptor ago-
nist–induced contraction of RAs.preparations of radial arteries from one patient. At 10 minutes after the ad-
dition of NA (1 mmol/L), fasudil was added in a cumulative fashion (0.1–30
mmol/L) at the indicated time points. The values are presented as means 
standard errors of the mean of the data from 3 rings. B, Dose-dependent in-
hibition of NA- and 5-hydroxytryptamine (5-HT)–induced contraction by
fasudil. Isometric tension of human radial artery rings from 3 patients stim-
ulated with NA (1 mmol/L) and 5-HT (1 mmol/L) is shown. Fasudil was
added to radial artery rings 10 minutes after agonist stimulation.
*P< .05, **P< .01, and ***P< .001 compared with nontreated radial
arteries.Fasudil Inhibits NA-Induced MYPT1
Phosphorylation
We studied the effects of fasudil and VG on NA-induced
phosphorylation of MYPT1 at the inhibitory phosphoryla-
tion site Thr853 in RA rings. NA induced about a 4-fold in-
crease in MYPT1 phosphorylation (Figure 2, B), indicating
that NA induced inhibition of MLCP. Pretreatment of
RA rings with fasudil abolished NA-induced MYPT1The Journal of Thoracic and Cardiovascular Surgery c Volume 142, Number 2 e61
FIGURE 2. Fasudil-induced inhibition of contraction is accompanied
by inhibition of myosin phosphatase targeting subunit 1 (MYPT1) phos-
phorylation in radial artery rings. A, Inhibition of noradrenaline (NA)–
and 5-hydroxytryptamine (5-HT)–induced contraction by various antispas-
modics. At 10 minutes after the addition of NA (1 mmol/L) or 5-HT
(1 mmol/L) to radial artery rings, relaxation was induced by adding either
fasudil, verapamil–glyceryl trinitrate (VG), olprinone, or papaverine at
a concentration of 30 mmol/L. The maximal relaxation responses were de-
termined after the addition of the drugs. *P<.05 and **P<.01 compared
with nontreated radial arteries. #P<.05 compared with olprinone-treated
radial arteries. yP<.05 compared with papaverine-treated radial arteries.
B, Inhibition by fasudil and VG of NA-induced phosphorylation of
MYPT1. Isometrically contracted or resting radial artery rings were rapidly
frozen at 10 minutes after the addition of fasudil or VG (n ¼ 3). **P<.01
compared with control. ##P< .01 compared with fasudil-treated radial
arteries.
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Sphosphorylation, suggesting that NA stimulates MYPT1
phosphorylation through ROCK (Figure 2, B). Paradoxi-
cally, VG alone induced an increase in MYPT1 phosphory-
lation. Pretreatment of RA rings with VG did not alter
NA-induced MYPT1 phosphorylation (Figure 2, B). These
observations suggest that fasudil, but not VG, inhibits
NA-induced contraction through inhibition of ROCK.
Intraluminal Application of Fasudil in Spastic RAs
Increases In Situ Free Blood Flow With Inhibition of
Phosphorylation of MYPT1 and MLC
In semiskeletonized spastic RAs intraluminal application
of either fasudil or VG significantly increased in situ free
blood flow (Figure 3, A). The increase in free blood flow be-
fore and after intraradial injections of antispasmodics was
greater in fasudil-treated RAs compared with that seen in
VG-treated RAs (Figure 3, B). The phosphorylation level
of MYPT1 in semiskeletonized spastic RAs was approxi-
mately 4-fold increased compared with that seen in pedicled
nonspastic RAs (Figure 4, A). Intraluminal injection ofFIGURE 3. Intraradial administration of fasudilmore effectively increases
in situ free blood flow in spastic radial arteries than verapamil–glyceryl tri-
nitrate (VG). A, In situ free blood flow in bilateral semiskeletonized spastic
radial arteries before and after infusion of either fasudil (left) or VG (right)
in 8 patients is shown. B, The changes in in situ free blood flow before and
after infusion of antispasmodics in bilateral radial arteries of 8 patients.
ery c August 2011
FIGURE 4. Intraradial administration of fasudil significantly inhibits
phosphorylation of myosin phosphatase targeting subunit 1 (MYPT1; A)
and myosin light chain (MLC; B) in skeletonization-induced spastic radial
arteries (RAs). Distal segments of pedicled nonspastic RAs and subse-
quently skeletonized spastic RAs before and after fasudil infusion were ex-
cised, rapidly frozen, and analyzed for phosphorylation of MYPT (A) or
MLC (B) by means of Western blotting. The data are derived from 3 to 5
values from different patients. *P<.05 and **P<.01 compared with ped-
icled RAs. #P<.05 and ##P<.01 compared with fasudil-treated RAs.




Sfasudil reduced MYPT1 phosphorylation to less than the
level of nonspastic RAs. Consistent with the results of
MYPT1 phosphorylation, the phosphorylation level of
MLC was 3-fold increased in spastic RAs compared with
that seen in nonspastic RAs, and fasudil injection decreased
MLC phosphorylation to the level seen in nonspastic RAsThe Journal of Thoracic and Ca(Figure 4, B). Intraradial application of fasudil or VG did
not acutely affect hemodynamic parameters, including sys-
temic blood pressure, heart rate, and cardiac output. Any
patient who underwent CABG by using fasudil-treated
RA grafts in the present study did not exhibit signs of myo-
cardial ischemia or low cardiac output during the perioper-
ative time period up to 72 hours after surgical intervention.
These observations suggest that ROCK-dependent inhibi-
tion of MLCP and the resultant increase in MLC phosphor-
ylation are involved in RA spasm and that fasudil
effectively deinhibits MLCP, decreases MLC phosphoryla-
tion, and thereby relieves RA spasm.
DISCUSSION
The following findings in the present study suggest the
usefulness of the ROCK inhibitor fasudil as a novel anti-
spasmodic agent. First, in isolated RA ring preparations fa-
sudil strongly inhibited contraction elicited by the 2 major
vasoactive receptor agonists NA and 5-HT with abolition
of agonist-induced stimulation of MYPT1 phosphorylation,
indicating that ROCK-mediated inhibition of MLCP plays
a crucial role in vasoconstrictor-induced contraction in
this artery. Second, semiskeletonized spastic RAs exhibited
enhanced ROCK activity compared with nonspastic RAs.
Third, intraradial administration of fasudil, but not VG, in-
hibited MYPT1 phosphorylation in spastic RAs and effec-
tively relieved vasospasm in situ. These observations
document that increased ROCK activity is critically in-
volved in RA spasm in CABG surgery and that fasudil is
a quite effective antispasmodic that acts through the novel
mechanism of ROCK inhibition.
Vasospasm in the RA is reported to occur in up to 10% of
cases perioperatively.23Arterial spasmduringgraft harvesting
is suggested to be caused by various physical stimuli, such as
mechanical stress resulting from the surgical procedure,
temperature stress produced by cooling, nervous stimuli,
and vasoactive humoral mediators.1,6-8 The spastic property
of the thick muscular wall and enhanced reactivity to
vasoactive mediators are implicated in higher susceptibility
to vasospasm of the RA.1,6 However, the exact mechanisms
of perioperative RA spasm remain unknown. Recently,
Rho- and ROCK-dependent inhibition of MLCP has been
shown to serve an essential role in vasoconstriction in various
vascular beds.12,13 Our data showed that on vasoactive
receptor agonist stimulation, ROCK-dependent MLCP inhi-
bition operates and substantially contributes to contraction
in nonspastic RAs (Figures 1 and 2). Importantly, the
present study showed that skeletonization-induced acute RA
spasm was accompanied by exaggerated MLCP inhibition
and consequent increased levels of MLC phosphorylation
(Figure 4), suggesting that the ROCK–MLCP pathway is
causally related to the pathogenesis of RA spasm.
The in vivo effectiveness of fasudil for RA spasm during
CABG surgery has been previously totally unknown. Therdiovascular Surgery c Volume 142, Number 2 e63




Spresent study demonstrated for the first time that intralumi-
nal administration of fasudil markedly increased in situ free
blood flow in spastic RAs and that the effect of fasudil was
much greater than that of the current standard antispas-
modic VG (Figure 3). Our data suggested that the antispas-
tic effect of fasudil was due to blockade of ROCK because
fasudil injection abolished an increase in MYPT1 phos-
phorylation at the ROCK phosphorylation site Thr853 and,
consequently, MLC phosphorylation (Figure 4). It should
be noted that the mechanisms of fasudil action are different
from those of other antispasmodic agents; VG by itself
rather increased MYPT1 phosphorylation in nonspastic
RAs and did not affect NA-induced MYPT1 phosphoryla-
tion (Figure 2, B). Glycerol trinitrate, a component of VG
mixture, releases nitric oxide and resultantly increases
levels of intracellular cyclic guanosine monophosphate.12
Cyclic guanosine monophosphate was previously shown
to inhibit Rho. However, the cyclic nucleotide also has in-
hibitory actions on Ca2þ channels and phospholipase C.9
Another component of VG, verapamil, is a Ca2þchannel an-
tagonist.6-8 Therefore it is likely that VG inhibits NA-
induced contraction through a mechanism independent of
ROCK-mediated MLCP inhibition. It remains to be clari-
fied how VG induced MYPT1 phosphorylation.
Previous studies implicated augmented ROCK activity in
the pathogenesis of various types of vasospasm; experimen-
tal vasospasm of coronary and cerebral vessels in animals
was accompanied by an increased vascular activity of
ROCK and enhanced MLCP inhibition.14-17 In patients
administration of fasudil alleviated vasospasm after
subarachnoid hemorrhage and coronary vasospasm.15-17
In a small number of patients shortly after CABG,
intracoronary infusion of fasudil relieved severe coronary
vasospasm.18 These observations suggest that augmented
MLCP inhibition might be involved in different types of va-
sospasm through increased MLC phosphorylation.
ROCK is also implicated in endothelial dysfunction,
which includes inhibition of the nitric oxide–synthesizing
enzyme exhaled nitric oxide synthase, upregulation of leu-
kocyte adhesion molecule expression, and upregulation of
proinflammatory cytokine expression.14 Therefore fasudil
might protect the endothelium from damage, leading to
the prevention of intimal proliferation, acceleration of ath-
erosclerosis, and thrombosis, which likely improves the
long-term patency of grafts.
In the present study intraradial administration of fasudil
did not affect the hemodynamic parameters or cause other
adverse effects, which is consistent with the reports in pa-
tients with cerebral vasospasm after subarachnoid hemor-
rhage who received fasudil administration.24 In the
present study the RA conduits remained dilated during
the operation after short-term fasudil treatment. None of
the 8 patients who had undergone grafting of fasudil-
treated RAs exhibited myocardial ischemia or cardiace64 The Journal of Thoracic and Cardiovascular Surgpump failure. Clinical trials of fasudil as an antispasmodic
agent need to be expanded for its further clinical
validation.
Adequate use of antispastic agents is crucial to maintain-
ing graft patency and avoiding myocardial ischemia perio-
peratively. Taking into consideration that fasudil was
a much more powerful antispasmodic than VG, which
was reported to be the optimum agent, it is concluded that
fasudil is a very effective new generation of antispasmodic
that acts through a distinct mechanism.
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